Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 03, 2023

BUY
$56.44 - $118.81 $104,414 - $219,798
1,850 Added 23.29%
9,792 $588,000
Q4 2022

Feb 06, 2023

BUY
$63.98 - $85.37 $445,620 - $594,602
6,965 Added 712.9%
7,942 $582,000
Q3 2022

Dec 01, 2022

SELL
$67.99 - $89.57 $91,446 - $120,471
-1,345 Reduced 57.92%
977 $74,000
Q3 2022

Oct 26, 2022

SELL
$67.99 - $89.57 $91,446 - $120,471
-1,345 Reduced 57.92%
977 $74,000
Q1 2022

Dec 01, 2022

BUY
$60.15 - $84.52 $108,751 - $152,812
1,808 Added 351.75%
2,322 $192,000
Q1 2022

Apr 26, 2022

BUY
$60.15 - $84.52 $139,668 - $196,255
2,322 New
2,322 $192,000
Q4 2021

Jan 31, 2022

SELL
$75.08 - $121.99 $38,591 - $62,702
-514 Closed
0 $0
Q3 2021

Dec 01, 2022

SELL
$116.17 - $194.55 $1.42 Million - $2.38 Million
-12,231 Reduced 95.97%
514 $60,000
Q3 2021

Oct 20, 2021

SELL
$116.17 - $194.55 $1.42 Million - $2.38 Million
-12,231 Reduced 95.97%
514 $60,000
Q2 2021

Dec 01, 2022

SELL
$130.4 - $225.58 $970,436 - $1.68 Million
-7,442 Reduced 36.87%
12,745 $2.83 Million
Q2 2021

Jul 28, 2021

SELL
$130.4 - $225.58 $970,436 - $1.68 Million
-7,442 Reduced 36.87%
12,745 $2.83 Million
Q1 2021

Dec 01, 2022

BUY
$124.11 - $190.17 $2.38 Million - $3.65 Million
19,210 Added 1966.22%
20,187 $2.67 Million
Q1 2021

Apr 23, 2021

BUY
$124.11 - $190.17 $531,314 - $814,117
4,281 Added 26.91%
20,187 $2.67 Million
Q4 2020

Dec 01, 2022

BUY
$112.16 - $174.14 $1.67 Million - $2.6 Million
14,929 Added 1528.05%
15,906 $2.75 Million
Q4 2020

Jan 28, 2021

BUY
$112.16 - $174.14 $1.78 Million - $2.77 Million
15,906 New
15,906 $2.75 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $2.75B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Robeco Institutional Asset Management B.V. Portfolio

Follow Robeco Institutional Asset Management B.V. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Robeco Institutional Asset Management B.V., based on Form 13F filings with the SEC.

News

Stay updated on Robeco Institutional Asset Management B.V. with notifications on news.